Core Insights - The company, Helus, is presenting results from its Phase II study in generalized anxiety disorder (GAD) and has two proprietary clinical programs, 003 and 004, with positive Phase II data [1][2] Company Overview - Helus has received FDA breakthrough therapy status for its lead program, 003, which is currently in Phase III for adjunctive treatment of major depressive disorder (MDD) [2] - The company has a strong intellectual property portfolio with over 350 filed patents, of which 100 are granted [2] Pipeline and Upcoming Catalysts - The pipeline includes two late-stage clinical development programs, 003 and 004, with a major catalyst expected in Q4 of this year, specifically the top line data from the first Phase III trial in MDD [3] - The company is focusing on the top line data from 004 in GAD, which is expected to be discussed in detail [3] Clinical Data Highlights - The company believes that 004 has an emerging best-in-class profile, supported by positive outcomes from both Phase I and Phase II studies [4] - In the Phase II study for GAD, there was a clinically meaningful 10-point reduction in the Hamilton Anxiety Rating Scale (HAM-A) at 6 weeks, with significant results observed as early as day 2 [4]